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Abstract
Objective The causative micro-organism in community-
acquired pneumonia (CAP) is often difficult to predict.
Different studies have examined chronic morbidity and
clinical symptoms as predictors for microbial aetiology of
pneumonia. The aim of our study was to assess whether
prior outpatient antimicrobial treatment is predictive for
determining the microbial aetiology of CAP.
Methods This was a hospital-based prospective observa-
tional study including all patients admitted with CAP
between 1 October 2004 and 1 August 2006. Microbial
investigations included sputum, blood culture, sputum
PCR, antigen testing and serology. Exposure to antimicro-
bial drugs prior to hospital admission was ascertained
through community pharmacy dispensing records. Multi-
variate logistic regression analysis was conducted to assess
whether prior outpatient antimicrobial treatment is a
predictor of microbial aetiology. Patient demographics, co-
morbidities and pneumonia severity were considered to be
other potential predictors.
Results Overall, 201 patients were included in the study. The
microbial aetiology was determined in 64% of the patients.
The five most prevalent pathogens were Streptococcus
pneumoniae, Heamophilus influenzae, Legionella spp., My-
coplasma pneumoniae and Influenza virus A+B. Forty-seven
of the patients (23%) had received initial antimicrobial
treatment as outpatients. Multivariate analyses revealed that
initial outpatient beta-lactam treatment was associated with a
threefold increased chance of finding atypical pathogens and
a threefold decreased probability of pneumococcal infection;
the corresponding odds ratios were 3.51 (95% CI 1.25–9.99)
and 0.30 (95% CI 0.10–0.90), respectively. Patients who
received macrolides prior to hospitalisation had an increased
probability of viral pneumonia.
Conclusion Prior outpatient antimicrobial therapy has a
predictive value inthe diagnosticworkup aimed atidentifying
the causative pathogen and planning corresponding antimi-
crobial treatment in patients hospitalised for pneumonia.
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Community-acquired pneumonia (CAP) remains a major
reason for hospital admission and a common cause of death
in developed countries [1, 2]. The initial management of
patients hospitalised with pneumonia consists mostly of
empirical antimicrobial treatment [3, 4]. Determination of the
appropriate antimicrobial treatment is essential as inadequate
antimicrobial treatment, generally defined as microbial
ineffective therapy against the causative pathogen, can
negatively influence patient outcome [5]. Because it is not
always possible to identify the causative pathogen, especially
during the first days following hospitalisation, many studies
have focussed on other parameters suggestive of the
causative pathogen. The most frequently studied parameters
for this purpose are patient characteristics (age and co-
morbidities) and clinical signs [6, 7], although nonrespon-
siveness to prior outpatient antimicrobial treatment has also
been suggested as a predictor of the aetiology of pneumonia.
However, to date, this latter parameter has not been
comprehensively quantified and documented. The aim of
the study reported here was to assess whether prior
outpatient antimicrobial treatment is a predictor of microbial
aetiology in patients admitted to hospital for CAP.
Methods
The study was conducted in the St. Antonius Hospital, a
600-bed teaching hospital in Nieuwegein, The Netherlands.
Patient population
This was a prospective observational study of patients with
confirmed pneumonia admitted between October 1, 2004
and August 1, 2006. Pneumonia was defined as a new or
progressive infiltrate on a chest X-ray plus at least two of
the following criteria: cough, sputum production, tempera-
ture >38°C or <35°C, ausculatory findings consistent with
pneumonia, leucocytosis or leucopenia (>10 g/l, <4 g/l or
>10% rods in leucocyte differentiation), C-reactive protein
>3 times the upper reference value for normal. Patients who
were immune compromised (systemic steroid use at
admission (prednisone equivalent >20 mg/daily for more
than 3 days), haematological malignancies and other
immunosuppressive therapy) were excluded. The study
was approved by the local Medical Ethics Committee, and
informed consent was obtained from each patient.
Microbial aetiology workup
At least two blood cultures were performed, and sputum was
taken for Gram-staining and culture and subsequently
analysedbyTaqman real-time PCRfor Mycoplasma pneumo-
niae, Legionella pneumophila and Chlamydophyla psittaci
[8]. Pharyngeal samples were taken for viral culture. Urine
was sampled for antigen testing on Streptococcus pneumo-
niae and L.pneumophila (Binax NOW; Binax, Scarborough,
ME) [9, 10]. In addition, serum samples taken on the day of
admission and on day 10 were analysed in pairs for detection
of a fourfold rise of antibodies to respiratory viruses,
Coxiella burnetii, M. pneumoniae,a n dC. psittaci by
complement fixation assay [11]. For each patient, the total
workup was completed, and the microbiology department
was blinded to data on outpatient antibacterial drug use.
When both viruses and bacteria were identified in a patient,
the search prevailed for a definite aetiology for the bacteria.
Exposure to antimicrobial therapy
Data on outpatient antimicrobial drug use were acquired
through community pharmacy dispensing records that
captured all drug exposures the year prior to hospital
admission. A patient was considered to be exposed to an
antimicrobial drug when a prescription was filled within
14 days prior to hospitalisation. The name, dosage and
amount of antimicrobial drug dispensed were also ascer-
tained. The prescribed antimicrobial drug was classified as
appropriate or inappropriate in accordance with current
Dutch guidelines on the initial treatment of patients with
suspected pneumonia [12, 13].
Co-morbidity assessment
In addition to outpatient antimicrobial drug use, co-
morbidities and other relevant patient characteristics were
identified to address factors related with the aetiology of
CAP. Co-morbidities were defined based on the presence of
conditions for which the patient was under active medical
supervision or was receiving treatment at the time of
hospital admission. The co-morbidities evaluated were
pulmonary diseases (chronic obstructive pulmonary disease
or treated asthma), congestive heart failure, diabetes (both
type I and type II), history of stroke and end-stage renal
disease (serum creatinine >150 μmol/l). The patients were
also classified according to the Pneumonia Severity Index
(PSI) developed by Fine et al. [14]. This index classifies
patients into five categories of predicted mortality risk (with
the fifth category being that of highest mortality risk). The
outpatient use of oral corticosteroids and gastric acid-
suppressing drugs was also ascertained.
Statistical analysis
The SPSS statistical package (ver. 12.0.1 for Windows;
SPSS, Chicago, IL) was used for the statistical analyses.
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median (interquartile range) where appropriate. To study
the association between prior outpatient antimicrobial
treatment and the aetiology of pneumonia, we applied
multivariate logistic regression analyses. The analyses were
conducted for overall aetiology and relevant pathogens
separately. All baseline characteristics were considered
potential predictors. Potential predictors were included in
the multivariate model when they were retained after
backward stepwise elimination. Significance was set at a
p value < 0.05. The model’s performance (goodness-of-fit
and discriminative ability) was tested by performing the
Hosmer and Lemeshow test and calculating the area under
the receiver operator characteristic (ROC) curve.
Results
In total, 201 patients with pneumonia were included in the
study. The mean age of the patients was 63±17 years, and
124 patients were male. Three patients (1%) were admitted
from a nursing home. Pneumonia severity as well as co-
morbid illnesses are summarised in Table 1. The overall
median duration of the hospital stay was 10 days [7 –14],
and 21 patients were admitted to the intensive care ward.
During the hospital stay, ten patients died, all due to
pneumonia. The overall 28-day mortality rate was 5%.
Forty-seven patients (23%) had received antimicrobial
treatment in the 14-day time-window prior to hospital
admission. The antimicrobial drugs dispensed to these
patients are summarised in Table 2.
The majority of the patients (79%) had their prescription
filled within 4 days prior to hospital admission, and 85% of
the prescribed antimicrobial drugs complied with current
Dutch guidelines [12, 13]. A microbial aetiology could be
determined in 128 (64%) of the patients. Table 3 shows the
results of different tests used to determine the aetiological
diagnosis of CAP.
Fewer causative pathogens were found in the population
hospitalised following prior outpatient antimicrobial treat-
ment than in patients without prior antimicrobial treatment
[57 vs. 66%; crude odds ratio (OR) 0.71, 95% confidence
interval (CI) 0.36–1.38]. In patients with prior beta-lactam
treatment, aetiology in the group comprising atypical
bacterial pathogens was more probable (eight of 29 cases,
28%; crude OR 4.66, 95% CI 1.73–12.56). The aetiology
of S. pneumoniae was less prevalent in patients with prior
beta-lactam antimicrobial treatment (four of 29 cases, 14%;
crude OR 0.33, 95% CI 0.11–0.99). In multivariate
analyses, these associations remained significant (OR
3.51, 95% CI 1.25–9.99 and OR 0.30, 95% CI 0.10–0.90,
respectively) (Table 4). Additional significant predictors
included in these models were heart failure, pulmonary
comorbidity, pneumonia severity index and the use of
gastric acid suppressing drugs. The goodness-of-fit of both
multivariate models was good, with a p value of 0.899
(Hosmer and Lemeshow test) for the model predicting
pneumococcal pneumonia and a p value of 0.995 for the
model predicting pneumonia of an atypical aetiology. The
corresponding areas under the ROC curve were 0.62 and
0.67, respectively.
Table 1 Demographics, co-morbidities and pneumonia severity index
of 201 patients with community-acquired pneumonia (CAP)
Characteristic n (%)
Age (Years)
<60 74 (37)
60–69 39 (19)
70–79 50 (25)
>80 38 (19)
Gender
Male 124 (62)
Female 77 (38)
Co-morbidities
Pulmonary diseases 71 (35)
Heart failure 18 (9)
Diabetes 35 (17)
History of stroke 17 (9)
End-stage renal disease 10 (5)
Nursing home resident 3 (1)
Co-medication
Oral corticosteroids 58 (29)
Gastric acid suppressing drugs 61 (30)
Fine score at admission
a
I 30 (15)
II 34 (17)
III 53 (26)
IV 56 (28)
V 28 (14)
aFine et al. [14]
Table 2 Outpatient antibiotics utilization profile prior to hospital-
isation for CAP
Type of antimicrobial drug Number of users (%)
a Appropriate
b
Amoxycillin/clavulanic acid 18 (38) Yes
Amoxycillin 12 (26) Yes
Doxycycline 7 (15) Yes
Clarithromycin 5 (11) Yes
Co-trimoxazole 4 (8) No
Ciprofloxacin 2 (4) No
Norfloxacin 1 (2) No
Azithromycin 1 (2) Yes
aTotal percentage exceeds 100% because some patients (n=3) had
two prescriptions
bBased on current Dutch guidelines NVALT and SWAB [12, 13]
Eur J Clin Pharmacol (2008) 64:405–410 407In patients aged <60 years without co-morbidities, the
aetiology of atypical bacterial pathogens was more preva-
lent (OR 4.64, 95% CI 1.72–12.56). Pulmonary co-
morbidity was associated with the finding of S. pneumoniae
and H. influenzae as causative pathogens (OR 1.87, 95% CI
1.00–3.47; OR 3.72, 95% CI 1.20–11.57, respectively).
Patients who received macrolides prior to hospitalisation
had an increased probability of viral pneumonia (two of
five cases, 40%) (crude OR 8.67, 95% CI 1.34–56.23).
Discussion
The results of our study show that among patients admitted
for CAP, a threefold decreased chance of having a S.
pneumoniae infection and a threefold increased probability
of having pneumonia of atypical aetiology were associated
with the patient having received an initial beta-lactam
treatment as an outpatient. These findings indicate that
information on prior outpatient antimicrobial therapy has a
predictive value in the diagnostic workup aimed at
identifying the causative pathogen and planning the
corresponding treatment in patients with pneumonia.
The initial management of patients hospitalised with
pneumonia has been under constant study in different
settings during the past decades. The choice of antimicro-
bial treatment, time to first antimicrobial drug administra-
tion and route of administration have all appeared to be
relevant factors associated with the outcome of pneumonia
[15–17]. A knowledge of the predominant microbial
patterns in CAP is therefore essential when choosing an
essential empirical antimicrobial treatment. Previous studies
have found that S. pneumoniae, H. influenzae, Influenza
virus A and B, Legionella spp. and C. pneumoniae are the
most frequent pathogens in CAP [13], which is in
accordance with our results. Because S. pneumoniae is the
most frequently appearing pathogen, the administration of
beta-lactam antibiotics is the initial empirical antimicrobial
treatment of choice in the treatment guidelines on CAP [3,
12, 13]. Beta-lactam antibiotics, however, do not cover
Legionella spp., C. pneumoniae and M. pneumoniae, the
so-called atypical pathogens. Therefore, patients with
pneumonia of atypical aetiology who are treated with
beta-lactam antibiotics as an outpatient will probably not
respond to treatment, with the possible consequence being a
deterioration of the situation and subsequent hospital
admission. Our finding of an increased prevalence of
Table 3 Results of of different tests used to determine the aetiology of CAP
Sputum culture Sputum PCR Antigen testing Blood culture Serology Viral culture
Number of samples 148 78 183 182 130 88
Number of positive samples 78 14 36 19 38 14
Percentage of positive samples 53 18 20 10 29 16
Streptococcus pneumoniae 33 – 30 17 ––
Gram-negative strain
Heamophilus influenzae 19 –– 0 ––
Other 10 –– 1 ––
Atypical
Mycoplasma pneumoniae – 7 –– 8 –
Legionella spp. 15 6– 7 –
Other – 2 –– 1 –
Viral –– –– 22 14
Other
S. aureus 6 –– 1 ––
Gram-positive other 2 –– 0 ––
Table 4 Odds ratios (OR) for aetiology and prior outpatient beta-
lactam treatment in patients admitted to hospital for CAP
Aetiology Prior outpatient beta-
lactam treatment
(n = no. of patients)
OR (95% CI)
Yes (%) No (%)
Total no. of samples 29 (100) 172 (100)
Univariate
Pneumococcal 4 (14) 56 (33) 0.33 (0.10–0.99)
Atypical 8 (28) 13 (8) 4.66 (1.72–12.56)
Viral 2 (7) 14 (8) 0.84 (0.18–3.89)
Gram-negative strains 2 (7) 21 (12) 0.53 (0.12–2.40)
Other 1 (3) 7 (4) 0.84 (0.10–7.11)
Unidentified 12 (41) 61 (36) 1.28 (0.58–2.87)
Multivariate
Pneumococcal –– 0.30 (0.10–0.90)
a
Atypical –– 3.51 (1.25–9.99)
b
OR, Odds ratio; CI, confidence Interval
aAdjusted for heart failure and use of gastric acid suppressing drugs
bAdjusted for pulmonary diseases and pneumonia severity index
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lactam treatment supports such an explanation, but also
confirms what has already been suggested in the different
guidelines for the management of community-acquired
pneumonia in adults [13, 18]. These guidelines state that
following the failure of the initial empirical treatment with
beta-lactam antibiotics, the microbiological examination
should be reassessed with a view to excluding the less
common pathogens, such as atypical pathogens, and that
antimicrobial treatment covering atypical pathogens should
be considered. Our study supports the choice of antimicro-
bial treatment covering atypical pathogens (e.g. macrolides)
for all patients with CAP who are admitted to hospital after
prior treatment with beta-lactam antibiotics. However,
whether this protocol will result in improved clinical
outcome should be subject to additional study.
The observed reduction in the frequency of S. pneumo-
niae in patients who received prior outpatient antimicrobial
treatment could also be due to a failure to detect the
organisms in cultures. This could mask S. pneumoniae as
the causative pathogen. However, we believe that this
explanation is less plausible, especially since we also used
antigen testing to identify the causative pathogen [19]. In
addition, such a mechanism can not explain the finding of
an increased probability of pneumonia caused by atypical
pathogens. To the best of our knowledge, our study is the
first to specifically document and quantify the failure of
initial outpatient antibiotic treatment as a predictor of the
microbial aetiology of CAP.
This study was conducted in a single teaching hospital in
The Netherlands, but we believe that the conclusions drawn
will apply to other settings. First, the percentage of
identified aetiology (64% in this study) is in agreement
with that of other studies using similar microbiological
techniques [20–22]. Second, our patient characteristics
comply to a great extent with a previous nationwide study
on prior outpatient antibacterial therapy as a prognostic
factor for mortality in patients hospitalised for pneumonia
[23]. In that large database study, the percentage of patients
hospitalised after initial outpatient antimicrobial treatment
was almost identical to that observed in our study (27 vs.
23%, respectively). In addition, age distribution, co-
morbidities and the antibiotic utilisation profile of the
outpatients were very similar as were the median duration
of hospital stay and in-hospital mortality. Unfortunately,
due to limited numbers, we were unable to study an
association between prior outpatient antimicrobial treatment
and mortality in our study. A very reassuring finding was
that 85% of all outpatient antibiotic prescriptions complied
with national guidelines on the initial treatment of adults
with suspected pneumonia. This reduces the possibility that
the findings, rather than being associated with antibiotics,
might reflect the diagnostic acumen of the physicians who
saw the patients in primary care. However, we cannot rule
out the possibility that typical signs of infection with
atypical pathogens may have been missed by primary care
physicians.
As well as finding a relation between prior antimicrobial
treatment and aetiology, we also found an association
between aetiology and age and pulmonary co-morbidity.
Patients aged <60 years without co-morbidities were more
likely to have an aetiology comprising viral or atypical
bacterial pathogens, and pulmonary co-morbidity was
independently associated with S. pneumoniae and H.
influenzae as causative pathogens. These findings confirm
the results of previous studies on the impact of age and co-
morbidity on the microbial aetiology of CAP [6]. A
limitation of the present study, however, is that we were
not able to adjust for smoking habits and alcohol intake of
the patients. Previous studies on determinants for pneumo-
nia aetiology found that these factors are significant
predictors of pneumococcal infection [6, 7]. On the other
hand, we do not expect prior antimicrobial therapy and
smoking and alcohol intake to coincide in such a way that
this would result in a null effect when all the information is
available.
In conclusion, among patients admitted for pneumonia,
whether or not a patient has received prior antimicrobial
therapy as an outpatient provides relevant information in
the diagnostic workup, in particular in terms of identify-
ing the causative pathogen and planning the initial
treatment at the time of hospital admission. This finding
supports a further strengthening of the continuity of care
at the interface between the extramural and hospitalised
settings.
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